#ASCO14 - Poster: Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study

CHICAGO, IL USA (UroToday.com) - Presented by Robert B. Montgomery, MD;1 Mario A. Eisenberger, MD;2 Elisabeth I. Heath, MD;3 A. Oliver Sartor, MD;4 Franklin Chu, MD;5 Neal D. Shore, MD;6 William Jeffery Edenfield, MD;7 Alan J. Koletsky, MD;8 David Uri Lipsitz, MD;9 James S. Cochran, MD;10 Luke T. Nordquist, MD;11 Jennifer Roberts;12 and Mary-Ellen Taplin, MD13 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 galeterone montgomery thumb

Click HERE to listen to an interview with Robert Bruce Montgomery, MD, one of the authors of the study

1University of Washington, Seattle, WA; 2The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; 3Karmanos Cancer Institute, Wayne State University, Detroit, MI; 4Tulane University, New Orleans, LA; 5San Bernadino Urological Associates, San Bernadino, CA; 6Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC; 7Cancer Centers of the Carolinas, Greenville, SC; 8Center for Hematology-Oncology, Boca Raton, FL; 9Carolina Urology, Concord, NC; 10Urology Clinics of North Texas, Dallas, TX; 11Urology Cancer Center and GU Research Network, LLC, Omaha, NE; 12Tokai Pharmaceuticals, Cambridge, MA; 13Dana–Farber Cancer Institute, Boston, MA